Glaxosmithkline Pharmaceuticals Ltd

Glaxosmi. Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Glaxosmithkline Pharmaceuticals Ltd

₹ 2,487 -1.28%
10 Mar - close price
gsk-india.com BSE: 500660 NSE: GLAXO
About

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)

Key Points

Leading Global Health care company[1] GlaxoSmithKline Pharmaceutical is a part of GlaxoSmithKline plc (GSK), a British multinational pharmaceutical company headquartered in London. GSK underwent a merger in 2000 of Glaxo Wellcome and SmithKline Beecham, and is the world’s sixth-largest pharmaceutical company.

Website BSE NSE
  • Market Cap ₹ 42,090 Cr.
  • Current Price ₹ 2,487
  • High / Low ₹ 3,516 / 2,220
  • Stock P/E 41.8
  • Book Value ₹ 101
  • Dividend Yield 1.69 %
  • ROCE 63.2 %
  • ROE 46.9 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 36.4%
  • Company has been maintaining a healthy dividend payout of 93.1%

Cons

  • Stock is trading at 24.7 times its book value
  • The company has delivered a poor sales growth of 3.06% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
802 787 762 957 805 930 815 1,011 949 974 805 980 1,041
574 618 618 668 587 673 584 689 658 641 554 644 670
Operating Profit 229 170 144 289 218 257 231 322 292 333 251 336 371
OPM % 29% 22% 19% 30% 27% 28% 28% 32% 31% 34% 31% 34% 36%
12 38 54 28 -135 32 36 39 35 41 44 36 50
Interest 0 1 0 0 0 1 0 0 0 1 0 1 1
Depreciation 16 17 16 18 17 18 16 17 19 15 16 17 20
Profit before tax 224 190 181 299 65 271 249 344 308 359 279 354 400
Tax % 27% 30% 27% 27% 30% 28% 27% 27% 25% 27% 27% 27% 26%
165 133 132 218 46 194 182 252 230 263 205 257 296
EPS in Rs 9.71 7.88 7.81 12.84 2.70 11.48 10.76 14.91 13.57 15.52 12.10 15.20 17.45
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Dec 2013 Mar 2015 15m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
2,563 3,305 2,838 2,908 2,871 3,128 3,224 2,926 3,278 3,252 3,454 3,749 3,801
2,034 2,672 2,360 2,489 2,363 2,527 2,567 2,327 2,516 2,447 2,545 2,570 2,509
Operating Profit 528 633 478 420 508 601 657 598 762 804 909 1,179 1,291
OPM % 21% 19% 17% 14% 18% 19% 20% 20% 23% 25% 26% 31% 34%
203 149 125 119 70 131 -262 9 1,401 103 -21 149 171
Interest 0 0 0 0 0 1 6 4 2 2 2 1 3
Depreciation 20 25 25 27 38 49 83 79 68 66 70 67 68
Profit before tax 711 756 578 511 540 683 306 525 2,093 839 816 1,260 1,391
Tax % 32% 37% 35% 34% 35% 35% 70% 32% 19% 27% 28% 26%
482 476 376 337 351 445 93 358 1,695 611 590 928 1,021
EPS in Rs 28.43 28.12 22.20 19.88 20.70 26.29 5.50 21.14 100.04 36.05 34.83 54.75 60.27
Dividend Payout % 88% 111% 113% 75% 85% 76% 727% 142% 90% 89% 92% 99%
Compounded Sales Growth
10 Years: 1%
5 Years: 3%
3 Years: 5%
TTM: 3%
Compounded Profit Growth
10 Years: 6%
5 Years: 43%
3 Years: -20%
TTM: 18%
Stock Price CAGR
10 Years: 4%
5 Years: 11%
3 Years: 24%
1 Year: -7%
Return on Equity
10 Years: 30%
5 Years: 45%
3 Years: 36%
Last Year: 47%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 85 85 85 85 85 169 169 169 169 169 169 169 169
Reserves 1,905 1,744 2,099 1,922 1,973 1,970 1,651 1,309 2,494 1,572 1,608 1,782 1,538
4 3 2 2 1 1 0 35 20 16 19 10 36
1,136 1,384 869 995 1,889 1,771 1,315 1,602 1,950 1,570 1,760 2,147 1,922
Total Liabilities 3,130 3,216 3,055 3,004 3,947 3,911 3,136 3,115 4,633 3,327 3,557 4,108 3,665
100 123 204 258 325 432 758 387 331 330 321 284 291
CWIP 62 115 268 605 923 1,003 120 13 30 20 14 14 17
Investments 10 0 6 0 0 0 0 0 366 518 813 1,118 1,313
2,958 2,977 2,577 2,140 2,700 2,477 2,257 2,715 3,907 2,458 2,408 2,692 2,044
Total Assets 3,130 3,216 3,055 3,004 3,947 3,911 3,136 3,115 4,633 3,327 3,557 4,108 3,665

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
281 338 139 234 473 409 490 578 811 484 582 1,290
189 180 499 301 -104 -153 -57 418 -406 808 9 -46
-494 -497 -638 -511 -307 -358 -428 -696 -524 -1,543 -562 -769
Net Cash Flow -24 21 -0 24 62 -102 6 300 -119 -251 29 475

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 14 11 16 21 19 14 11 27 23 22 23 28
Inventory Days 109 91 156 111 147 131 135 159 144 131 144 126
Days Payable 90 74 97 73 149 109 100 135 156 122 171 186
Cash Conversion Cycle 33 27 75 60 17 36 46 50 11 31 -4 -31
Working Capital Days -45 -48 26 7 -90 -72 -38 -39 -94 -57 -64 -99
ROCE % 34% 42% 29% 22% 26% 31% 33% 38% 37% 36% 51% 63%

Insights

In beta
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Number of Employees
Count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Packs Distributed Annually
Million Packs ・Standalone data
Manufacturing Capacity (Nashik Plant Tablets)
Billion Tablets ・Standalone data
Market Share of Key Promoted Brands
% ・Standalone data
Overall Industry Ranking (by value)
Rank ・Standalone data
Daily Unit Doses Distributed
Billion Unit Doses ・Standalone data
Number of Contract Manufacturing Units (CMOs)
Count ・Standalone data
Unique Healthcare Professionals (HCP) Reach
Count ・Standalone data
Number of Medical Representatives (Sales Force)
Count ・Standalone data

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00%
2.28% 2.41% 2.50% 2.93% 3.48% 4.02% 4.36% 4.50% 4.52% 4.89% 4.79% 4.63%
10.31% 10.25% 10.01% 8.64% 7.90% 7.51% 7.34% 7.30% 7.79% 7.71% 7.75% 7.70%
0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
12.43% 12.35% 12.48% 13.42% 13.62% 13.48% 13.30% 13.21% 12.69% 12.41% 12.45% 12.67%
No. of Shareholders 1,20,4151,19,0321,15,2681,14,6631,18,9941,18,5151,19,2281,19,6251,21,8851,23,6291,22,9041,22,460

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls